Item 8.01 Other Events.

On October 13, 2008, Neurobiological Technologies, Inc. (the "Company") issued a press release announcing that, following a meeting with the U.S. Food and Drug Administration to discuss the Viprinex™ (ancrod) Phase 3 clinical program for acute ischemic stroke, the Company plans to consolidate and analyze data from its two concurrently running double-blind clinical trials into a single Phase 3 pivotal trial. The Company also announced that the previously announced interim futility analysis based on the first 500 treated patients is estimated to be completed by January 2009, and that the interim review would not include a superiority analysis following the combination of the trials. A copy of this press release is filed herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release, dated October 13, 2008